The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $57.79

Today's change+1.28 +2.27%
Updated January 19 4:02 PM EST. Delayed by at least 15 minutes.
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $57.79

Today's change+1.28 +2.27%
Updated January 19 4:02 PM EST. Delayed by at least 15 minutes.

Novo Nordisk A/S Hits New 52-week High

Novo Nordisk A/S closed up sharply Friday, rallying (U.S.)$1.28 or 2.27% to (U.S.)$57.79 and setting a new 52-week high. Over the last five days, shares have gained 5.00% and outperformed the S&P 500 index over the last 52 weeks with a 62.19% increase in price.

Key company metrics

  • Open(U.S.) $57.43
  • Previous close(U.S.) $56.51
  • High(U.S.) $57.82
  • Low(U.S.) $57.35
  • Bid / Ask-- / --
  • YTD % change+7.68%
  • Volume2,094,025
  • Average volume (10-day)954,855
  • Average volume (1-month)1,031,720
  • Average volume (3-month)1,579,582
  • 52-week range(U.S.) $32.83 to (U.S.) $57.82
  • Beta0.58
  • Trailing P/E22.73×
  • P/E 1 year forward23.99×
  • Forward PEG2.86×
  • Indicated annual dividend(U.S.) $1.14
  • Dividend yield1.98%
  • Trailing EPS(U.S.) $2.54
Updated January 19 4:02 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+34.05%

Based on its net profit margin of 34.05%, Novo Nordisk A/S is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.42%Sector:Industry:

Latest Company News

View more News
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2017Q2/2017Q1/2017Q4/2016
Fiscal Quarter Endvalues in $ millions unless otherwise notedSep 30, 201709/30/2017Jun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016
Revenue26,61428,63828,45229,572
Total other revenue--------
Total revenue26,61428,63828,45229,572
Gross profit22,34224,22924,20124,654
Total cost of revenue4,2724,4094,2514,918
Total operating expense14,57015,25214,96218,366
Selling / general / administrative7,3937,6187,7009,075
Research & development3,3283,4143,2894,470
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total-423-189-278-97
Operating income12,04413,38613,49011,206
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax12,46212,64313,00410,942
Income after tax9,7709,95110,1568,699
Income tax, total2,6922,6922,8482,243
Net income9,7709,95110,1568,699
Total adjustments to net income--------
Net income before extra. items9,7709,95110,1568,699
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items9,7709,95110,1568,699
Inc. avail. to common incl. extra. items9,7709,95110,1568,699
Diluted net income9,7709,95110,1568,699
Dilution adjustment0000
Diluted weighted average shares2,4692,4842,5002,517
Diluted EPS excluding extraordinary itemsvalue per share3.964.014.063.46
Dividends per sharevalue per share0.002.950.006.77
Diluted normalized EPSvalue per share3.964.014.063.46